Miraculins reports that it is licensing a portfolio of biomarkers from Mount Sinai Hospital for use in diagnostic assays for the early detection of preeclampsia.
The signing of the term sheet between these organizations includes the biomarker endoglin, a cell surface glycoprotein. Recent studies have shown that it increases in week 17–20 of gestation and that it also plays a role in identifying the highest risk patients.